KR20100098394A - 암 치료제로서의 키네신 억제제 - Google Patents

암 치료제로서의 키네신 억제제 Download PDF

Info

Publication number
KR20100098394A
KR20100098394A KR1020107012912A KR20107012912A KR20100098394A KR 20100098394 A KR20100098394 A KR 20100098394A KR 1020107012912 A KR1020107012912 A KR 1020107012912A KR 20107012912 A KR20107012912 A KR 20107012912A KR 20100098394 A KR20100098394 A KR 20100098394A
Authority
KR
South Korea
Prior art keywords
substituted
carcinoma
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107012912A
Other languages
English (en)
Korean (ko)
Inventor
티냐 아브람스
Paul Barsanti
데이비드 둘
미셸 포레
폴 에이. 레노우
안네테 올가 발터
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20100098394(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20100098394A publication Critical patent/KR20100098394A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107012912A 2007-12-14 2008-12-12 암 치료제로서의 키네신 억제제 Withdrawn KR20100098394A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
US61/013,966 2007-12-14

Publications (1)

Publication Number Publication Date
KR20100098394A true KR20100098394A (ko) 2010-09-06

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012912A Withdrawn KR20100098394A (ko) 2007-12-14 2008-12-12 암 치료제로서의 키네신 억제제

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
WO2011128388A2 (en) * 2010-04-15 2011-10-20 Novartis Ag Oxazole and thiazole compounds as ksp inhibitors
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
MX392478B (es) * 2015-06-22 2025-03-24 Bayer Pharma AG Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002236A1 (en) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
CA2674318A1 (en) 2007-01-05 2008-07-17 Novartis Ag Cyclized derivatives as eg-5 inhibitors

Also Published As

Publication number Publication date
PA8807801A1 (es) 2009-07-23
TW200930704A (en) 2009-07-16
PE20091451A1 (es) 2009-10-19
EP2229170B1 (en) 2014-01-22
JP2011506402A (ja) 2011-03-03
ES2459442T3 (es) 2014-05-09
MA31872B1 (fr) 2010-11-01
MY150214A (en) 2013-12-13
US8664256B2 (en) 2014-03-04
CO6290651A2 (es) 2011-06-20
EA018014B1 (ru) 2013-04-30
UY31532A1 (es) 2009-08-03
IL205831A0 (en) 2010-11-30
DOP2010000175A (es) 2010-06-30
EA201000900A1 (ru) 2011-02-28
GT201000172A (es) 2012-04-30
ECSP10010248A (es) 2010-07-30
SMAP201000095A (it) 2010-09-10
US8252832B2 (en) 2012-08-28
US20090239922A1 (en) 2009-09-24
CN101939005B (zh) 2015-12-16
CN101939005A (zh) 2011-01-05
TN2010000204A1 (en) 2011-11-11
AU2008337570A1 (en) 2009-06-25
AU2008337570B2 (en) 2012-04-05
BRPI0821248A2 (pt) 2015-06-16
JP5501976B2 (ja) 2014-05-28
US20130012560A1 (en) 2013-01-10
SMP201000095B (it) 2011-09-09
GEP20125647B (en) 2012-09-25
NZ585142A (en) 2012-03-30
CL2008003707A1 (es) 2009-06-05
NI201000091A (es) 2011-03-15
AR069676A1 (es) 2010-02-10
CA2708822A1 (en) 2009-06-25
EP2229170A1 (en) 2010-09-22
CR11412A (es) 2010-06-30
WO2009077448A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
JP5501976B2 (ja) 癌治療薬としてのキネシン阻害剤
ES2718900T3 (es) Inhibidores de EZH2 humana y métodos de uso de los mismos
EP3275442A1 (en) Therapeutic agent for bile duct cancer
KR20220133258A (ko) 화합물 및 이의 용도
US20150152088A1 (en) Alkynyl heteroaromatic compound and use thereof
KR20180032596A (ko) 성인 t 세포 백혈병 림프종의 치료 및/또는 예방제
JP2007084494A (ja) Ｐｉｍ−１活性阻害剤
KR102338568B1 (ko) 퀴나졸린 유도체
EP4495115A1 (en) Tetracyclic compound and use thereof
US10308597B2 (en) Inhibitors of creatine transport and uses thereof
US11267809B2 (en) BAF complex modulating compounds and methods of using the same
ES2280502T3 (es) Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de integrinas.
US20230218708A1 (en) Compositions and methods of targeting cancer stem cells
US10329626B2 (en) NOL3 is a predictor of patient outcome
WO2016176636A1 (en) Inhibitors of creatine transport and uses thereof
EP4433462A1 (en) Usp9x inhibitors
US20230227418A1 (en) Usp9x inhibitors
CN117323332B (zh) 蛋白激酶ck2抑制剂在增强肝癌治疗疗效中的应用
RU2809720C2 (ru) Применение производного инденофлуорена для ингибирования и/или элиминации опухолевых клеток
WO2023008533A1 (ja) 膵臓がん及び胆管がんの治療のための医薬用組成物
WO2023091464A1 (en) Usp9x inhibitors
KR20240128955A (ko) 암 치료제로서의 강력하고 선택적인 smarca2 분해 키메라 분자
WO2025034569A9 (en) Sting inhibitors and methods of using thereof
PL213249B1 (pl) Zastosowanie pochodnych semikarbazydowych oraz 1,2,4-triazolino-5-onu posiadających układ 1-metylopirolu
CN106714802A (zh) 癌细胞增殖抑制剂、抗癌药及它们的筛选方法、以及新型化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100611

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid